FDA Clears Regeneron's Quarterly RNA Shot Livsayis for Myasthenia Gravis
Regeneron's Livsayis (cemdisiran) won FDA approval Wednesday for adults with generalized myasthenia gravis who test positive for acetylcholine receptor antibodies. It's an siRNA that cuts C5 production in the liver, dosed once every three months, and it beat placebo on daily-living and strength scores in the NIMBLE trial. A boxed warning for meningococcal infections and a restricted REMS program come attached.
- Original source: techtimes.com.
- The source published it on Nov 19, 2026 at 6:48 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA signed off on Livsayis (cemdisiran), an injectable RNA drug for adults with generalized myasthenia gravis who carry antibodies against the acetylcholine receptor. Regeneron announced the approval at 6:03 p.m. ET on Wednesday, Nov. 18. Patients get one shot every three months instead of weekly, daily or infused alternatives, but the label carries a boxed warning for serious meningococcal infections and access runs through a restricted program called the Livsayis REMS. Regeneron puts the U.S. myasthenia gravis population at about 85,000 people.
Approval rests on NIMBLE, a randomized, double-blind, placebo-controlled Phase 3 trial across 86 centers in 13 countries. The monotherapy arm took 600 mg every 12 weeks and improved 4.5 points on MG-ADL, a patient-reported measure of speaking, chewing and breathing, against 2.2 points for placebo — a placebo-adjusted gain of 2.3 points (P=.0005). On the clinician-scored QMG strength exam, Livsayis gained 4.2 points versus 1.5 for placebo, a 2.8-point difference (P=.0015). Regeneron reports improvement as early as two weeks after the first dose.
Adding Regeneron's antibody pozelimab didn't move the needle. The combination's placebo-adjusted MG-ADL gain was 1.74 points, smaller than the 2.3 points for cemdisiran alone. Tuan Vu of the University of South Florida, who led the NIMBLE team, said the combo gave no additional advantage. In topline results, Regeneron reported average complement inhibition of 74% with cemdisiran alone versus nearly 99% with the combination, and an executive said robust efficacy can be achieved without complete complement blockade.
Livsayis works one step upstream of older C5 drugs like Soliris and Ultomiris, which bind the protein after the liver builds it. It's a small interfering RNA that cleaves the messenger RNA carrying C5's instructions, tagged with a sugar called GalNAc that pulls it into liver cells via the ASGPR receptor. In healthy volunteers, drug levels peaked within an hour of injection and dropped sharply in about eight hours, yet C5 suppression lasted months — one analysis reported it held up to 13 months after single and multiple doses.
That long tail explains the meningococcal warning. C5 helps assemble the membrane attack complex, a key weapon against Neisseria bacteria, and the CDC links eculizumab (Soliris) to a 1,000-fold to 2,000-fold higher incidence of meningococcal disease, with 16 U.S. cases among recipients from 2008 to 2016 — 14 of whom had received at least one meningococcal vaccine dose. Livsayis patients must finish vaccination at least two weeks before the first dose, or take antibiotics if they start sooner, enroll in the REMS, carry a safety card during treatment and for 12 months after the last dose, and the drug is contraindicated in active meningococcal infection. NIMBLE's double-blind period logged no meningococcal infections or deaths, with adverse events in 69.2% of cemdisiran patients versus 77.1% on placebo; one patient with substantial comorbidities on immunosuppressants died of pneumonia in the open-label extension.
The approval lands days after the FDA cleared Alexion's Klygefa (gefurulimab), a weekly self-injected C5 blocker Drugs.com lists as first approved Nov. 13. Livsayis now competes with Soliris, Ultomiris, Zilbrysq and Klygefa among complement inhibitors, plus three FcRn-targeting drugs. Pharmaphorum cites estimates that 20% to 50% of real-world patients respond inadequately to their first gMG treatment; Vu told NeurologyLive the burden with a shot every three months is 'really low.' Leerink Partners analyst David Risinger judged in 2025 that cemdisiran's efficacy falls short of FcRn blockers while landing roughly on par with AstraZeneca's C5 inhibitors, and GlobalData forecasts peak sales of $1.9 billion.
TopicsRegeneron · Livsayis · FDA · Klygefa · Alexion · Soliris · AstraZeneca · Tuan Vu
Source: techtimes.com
Written by AI from verified reporting.
More stories
- Health & science reuters.com Caught by @Coen 1 viewFDA stands up internal council to vet vaccines and gene therapies after approval
- Health & science medicalxpress.com Caught by @boxlink 4 viewsThe brain builds a word blueprint a quarter-second before you speak, UCSF finds
- Health & science adelaide.edu.au Caught by @boxlink 2 viewsAdelaide quantum team ditches hundreds of loops, keeps sensor sensitivity
- Health & science multiplesclerosisnewstoday.com 2 viewsFDA opens access to Neurogenesis stem cell therapy for progressive MS

